معرفی
Thomas Mavrakanas, MD, M.Sc. is an Associate Professor at the Department of Medicine, Faculty of Medicine and Health Sciences, McGill University. He serves as a Scientist at the Research Institute of the McGill University Health Centre (RI-MUHC), specifically within the Cardiovascular Health Across the Lifespan Program. His research focuses on cardiovascular disease in patients with advanced chronic kidney disease (CKD), emphasizing two key areas: cardiorenal interactions and anticoagulation in CKD.
- Academic affiliation: Associate Professor, McGill University
- Research focus: Cardiorenal syndromes, Anticoagulation, CKD
- Key techniques: Clinical trials, Pharmacokinetic studies, Observational research
Mavrakanas has led multiple clinical trials, including CARe-MRI (NCT06182839) to assess canagliflozin's impact on cardiac structure in advanced CKD, and CAN-PD to evaluate its effects on peritoneal dialysis patients. His work aims to prevent myocardial infarction, stroke, and heart failure while slowing CKD progression.
His research output spans systematic reviews, meta-analyses, and pharmacokinetic studies, with recent work addressing SGLT2 inhibitors, mineralocorticoid receptor antagonists, and diuretic resistance in heart failure. Despite his prolific publication record, no explicit awards or student mentorship details are mentioned in the provided texts.
